研究人員在1月24日出版的美國《癌癥》（Cancer）期刊上發(fā)表文章說，常用乳腺癌治療藥物它莫西芬可能有助于降低肺癌致死風險,。
先前研究顯示,，女性在絕經(jīng)期采取荷爾蒙替代療法刺激雌激素分泌,，會增加患乳腺癌、肺癌或卵巢癌的風險,。
它莫西芬是一種抗雌激素,，能夠抑制部分乳腺癌細胞生長和分裂。研究人員假設(shè),，這類抗雌激素在阻止雌激素分泌的同時,，可能降低肺癌致死風險。
這個研究團隊在瑞士日內(nèi)瓦一家癌癥統(tǒng)計機構(gòu)選取6655名女性的數(shù)據(jù),，這些女性1980年至2003年間確診患乳腺癌,，其中3066人服用抗雌激素藥物。
研究人員追蹤截至2007年12月的全部乳腺癌患者病情進展,，統(tǒng)計其中罹患肺癌和肺癌致死人數(shù),。
結(jié)果顯示，與普通人群相比,，這3066名服用抗雌激素藥物的乳腺癌患者中,，肺癌致死人數(shù)減少87%。
研究領(lǐng)隊伊麗莎白·拉皮蒂說,，統(tǒng)計結(jié)果支持研究假設(shè),，即體內(nèi)荷爾蒙水平與肺癌存在關(guān)聯(lián)，大部分乳腺癌患者罹患肺癌,，與服用孕酮等雌激素有關(guān),。
拉皮蒂說,，如果進一步研究能夠證實這些統(tǒng)計結(jié)果，找到抗雌激素類藥物有助于緩解肺癌的證據(jù),，將對今后臨床研究產(chǎn)生重要影響,。（生物谷Bioon.com）
生物谷推薦原文出處：
Cancer DOI: 10.1002/cncr.25638
Lung cancer mortality risk among breast cancer patients treated with anti-estrogens
Christine Bouchardy MD1,*,§, Simone Benhamou DSc2,3, Robin Schaffar MSc1, Helena M. Verkooijen MD1,4, Gerald Fioretta MSc1, Hyma Schubert MSc1, Vincent Vinh-Hung MD5, Jean-Charles Soria MD6, Georges Vlastos MD7, Elisabetta Rapiti MD1
Keywords:lung cancer;breast cancer;mortality risk;anti-estrogens;epidemiology;population-based study
Abstract
BACKGROUND:
The Women's Health Initiative randomized clinical trial reported that menopausal hormone therapy increases lung cancer mortality risk. If this is true, use of anti-estrogens should be associated with decreased lung cancer mortality risk. The authors compared lung cancer incidence and mortality among breast cancer patients with and without anti-estrogen therapy.
METHODS:
Our study included all 6655 women diagnosed with breast cancer between 1980 and 2003 and registered at the Geneva Cancer Registry. Among these women, 46% (3066) received anti-estrogens. All women were followed for occurrence and death from lung cancer until December 2007. The authors compared incidence and mortality rates among patients with and without anti-estrogens with those expected in the general population by Standardized Incidence Ratios (SIRs) and Standardized Mortality Ratios (SMRs).
RESULTS:
After a total of 57,257 person-years, 40 women developed lung cancer. SIRs for lung cancer were not significantly decreased among breast cancer patients with and without anti-estrogens (0.63, 95% confidence intervals [CI], 0.33-1.10; and 1.12, 95% CI, 0.74-1.62, respectively) while SMR was decreased among women with anti-estrogens (0.13, 95% CI, 0.02-0.47, P<.001) but not for women without anti-estrogens (0.76, 95% CI, 0.43-1.23).
CONCLUSIONS:
Compared with expected outcomes in the general population, breast cancer patients receiving anti-estrogen treatment for breast cancer had lower lung cancer mortality. This study further supports the hypothesis that estrogen therapy modifies lung cancer prognosis. Cancer 2011. ? 2011 American Cancer Society.
